NEW DELHI : Pharmaceutical firm Hetero on Monday said the Drug Controller General of India (DCGI) has approved Emergency Use Authorization (EUA) for its generic version of Tocilizumab for the treatment of covid-19 in hospitalized adults.
This authorization will enable medical practitioners in India to use the drug for patients who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), the company said in a statement.
Hetero’s Tocira will be marketed by its associate company Hetero Healthcare in India with the support of its strong distribution network across the country.